The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China

Table 2 Base-case results: cost-effectiveness of once-weekly semaglutide 0.5 mg and 1 mg versus sitagliptin 100 mg when added to metformin (per patient)

	Semaglutide 0.5 mg + metformin	Semaglutide 1 mg + metformin	Sitagliptin 100 mg + metformin
Discounted QALYs	12.23	12.27	12.15
Discounted Costs, ¥ ($) ^†	248,546 (36,893)	235,279 (34,923)	283,394 (42,065)
Incremental QALYs	0.08	0.12	–
Incremental Costs, ¥ ($) ^†	–34,848 (–5173)	–48,115 (–7142)	–
ICER (cost per QALY gained)	Semaglutide 0.5 mg + metformin dominant ^‡	Semaglutide 1 mg + metformin dominant ^§	–

ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year
^† For the costs, data are 2022 Chinese yuan, ¥ (2022 US dollar, $). One US dollar was equal to ¥6.737 in 2022 [19]
^‡ Once-weekly semaglutide 0.5 mg + metformin dominated sitagliptin + metformin with more QALYs and lower costs
^§ Once-weekly semaglutide 1 mg + metformin dominated sitagliptin + metformin with more QALYs and lower costs

ISSN: 2191-1991